Thetis Pharmaceuticals
Phase 1Thetis Pharmaceuticals develops TP-317, a first-in-class oral BLT1 agonist based on Resolvin E1 for inflammatory bowel disease and solid tumor cancers.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $18M
About
Thetis Pharmaceuticals develops TP-317, a first-in-class oral BLT1 agonist based on Resolvin E1 for inflammatory bowel disease and solid tumor cancers.
Small Molecules
Funding History
2Total raised:$18M
Series A$15MMay 15, 2022
Seed$3MSep 15, 2020